)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Alivus Life Sciences
Alivus Life Sciences (ALVUS) investor relations material
Alivus Life Sciences Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary30 Oct, 2026
Executive summary
Q2 FY27 revenue was ₹6,819.87m, up 16.0% YoY, supported by broad-based demand, launches and stronger CDMO activity.
Improved product mix and operating efficiencies lifted EBITDA margin to 41.8% and PAT margin to 28.9%; adjusted EBITDA margin excluding one-time income was ~39.5%.
Financial highlights
Q2 revenue rose 16.0% YoY; H1 FY27 revenue was ₹13,224.01m, up 11.1% YoY.
Q2 EBITDA was ₹2,851m, up 47.0% YoY; H1 EBITDA was ₹5,192m, up 38.4%.
Q2 net profit was ₹1,967.45m, up 51.3% YoY; H1 net profit was ₹3,568.21m, up 41.9%.
Q2 gross margin was 64.4%, up 420 bps QoQ and 670 bps YoY; H1 gross margin was 62.3%, up 590 bps YoY.
H1 operating cash flow was ₹4,596.91m, compared with ₹2,607.29m in H1 FY26.
Outlook and guidance
FY27 revenue growth guidance of 10%-12% and EBITDA-margin guidance of 35%-36% were reaffirmed; management expects a stronger H2 contribution.
CDMO revenue is expected to exceed last year; the longer-term target is to double the business to 12%-15% of revenue over 3-4 years.
Planned capacity additions include ~100 KL at Ankleshwar by Q4 FY27, ~160 KL at Dahej by Q3 FY27 and 535 KL at Solapur by FY29.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Alivus Life Sciences
- FY22 profit rose 19.1% as core API demand and capacity investment advanced.ALVUS
Q4 21/22 - FY24 growth and margin gains support a capacity-led expansion despite external risks.ALVUSQ4 23/24
- Profit and margins improved as Generic API growth offset a softer product-sales base.ALVUSQ4 22/23
- Q1 FY27 saw strong revenue and margin growth, driven by non-GPL and regulated markets.ALVUSQ1 26/27
- Record Q3FY26 revenue and margins driven by CDMO growth, Non-GPL strength, and solid outlook.ALVUSQ3 25/26
- Q2 FY26 revenue up 16% YoY, 33% EBITDA margin, strong non-GPL growth, and robust cash flow.ALVUSQ2 25/26
- Q1 FY25 saw 9.7% revenue growth, margin gains, and a regulatory halt at Ankleshwar.ALVUSQ1 24/25
- Q4 revenue up 21.1% YoY, EBITDA margin 32.1%, FY2026 guided for mid-teens volume growth.ALVUSQ4 24/25
- Q3FY25 saw 12% revenue growth, record margins, and strong cash flow, with growth investments prioritized.ALVUSQ3 24/25
Next Alivus Life Sciences earnings date
Q3 26/2721 Jan, 2027
Alivus Life Sciences
Next Alivus Life Sciences earnings date
Q3 26/2721 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)